Boehringer and Lonza question the future of FDA's regulation of AI in manufacturing
The FDA opened the floor for comments on its discussion paper on the use of AI in drug manufacturing, with interest groups and manufacturers in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.